Jet Airways in doldrums
Jet Airways in doldrums

Jet Airways in doldrums

Amir Shaikh Article rating: 4.7

After flying for the last 26 years the Indian airline, Jet Airways stopped operation in April 2019 as it failed to get emergency funding to keep its operation going on. 

5 personal finance habits to inculcate
5 personal finance habits to inculcate

5 personal finance habits to inculcate

Henil Shah Article rating: 5.0

Personal finance is one aspect where everyone must dive into and look whether it is doing well or requires some tweaks to get it on track. Read on to find out more on what are the good personal finance habits to inculcate?

Garden Reach bags orders, stock shines
Garden Reach bags orders, stock shines

Garden Reach bags orders, stock shines

Amir Shaikh Article rating: 5.0

The government-owned Garden Reach Shipbuilders & Engineers firm on Monday informed the bourses that it has entered into a contract with the Government of India, Ministry of Defence, for orders worth Rs. 6,311.32 crore.

Cadila, SIFI to market Innovative Intraocular Lenses
Cadila, SIFI to market Innovative Intraocular Lenses

Cadila, SIFI to market Innovative Intraocular Lenses

Nidhi Jani Article rating: 5.0

Zydus Cadila and global Pharma major SIFI announced that they have tied-up to market innovative IOLs (Intraocular lenses) and surgical products developed in Italy and licensed in India by SIFI to treat ophthalmic disorders in the Indian market.

Max India to explore new lines of business
Max India to explore new lines of business

Max India to explore new lines of business

Advait Dharmadhikari Article rating: 5.0

Max India is set to enter businesses with adjacencies to current group businesses of life insurance, real estate, senior care and hospitality. The company is in the midst of selling 51 per cent stake in Health Insurance JV Max Bupa, to a leading private equity firm True North which is expected to be completed in the next six months.

Cipla: Subsidiary receives USFDA nod for Ambrisentan tablets
Cipla: Subsidiary receives USFDA nod for Ambrisentan tablets

Cipla: Subsidiary receives USFDA nod for Ambrisentan tablets

Shohini Nath Article rating: 5.0

Cipla with its subsidiary, Cipla USA has received approval for ANDA for Ambrisentan Tablets from the US drug regulator. The shares of the company were trading in red in the morning session.

Yes Bank down 25 per cent on weak Q4 results
Yes Bank down 25 per cent on weak Q4 results

Yes Bank down 25 per cent on weak Q4 results

Gayathri Udyawar Article rating: 5.0

Leading private banker Yes Bank's shares tumbled on Tuesday as the bank posted a loss of Rs. 1,507 crore for the March quarter. In the early morning session on Tuesday, the stock was down by more than 25 per cent at Rs. 177.90 per share.

Glenmark launches anti-diabetes drug Remogliflozin in India
Glenmark launches anti-diabetes drug Remogliflozin in India

Glenmark launches anti-diabetes drug Remogliflozin in India

Advait Dharmadhikari Article rating: 5.0

Glenmark announced the launch of its patent-protected and globally-researched sodium glucose co-transporter-2 (SGLT2) inhibitor Remogliflozin etabonate in India. The drug is indicated in the treatment of type-2 diabetes mellitus in adults.

Five stocks with selling interest
Five stocks with selling interest

Five stocks with selling interest

Shital Jibhe Article rating: 3.5

Overall volumes in futures & options currently stand at 1.10 crore contracts with a turnover of Rs. 7,32,837.82 crore.

Five stocks with buying interest
Five stocks with buying interest

Five stocks with buying interest

Shital Jibhe Article rating: 5.0

Overall volumes in futures & options currently stand at 1.10 crore contracts with a turnover of Rs. 7,32,837.82 crore.

RSS
First27012702270327042706270827092710Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR